Dosimetric and Radiobiological Evaluation of Multiparametric MRI-Guided Dose Painting in Radiotherapy of Prostate Cancer
DOI:
Abstract
Radiotherapy is one of the treatment options for locally advanced prostate cancer; however, with standard radiation doses, it is not always very effective. One of the strategies to improve the efficiency of radiotherapy is increasing the dose. In this study, to increase tumor local control rates, a new radiotherapy method, known as dose painting (DP), was investigated. To compare 3-dimensional conformal radiotherapy (3D-CRT) and intensity modulated radiotherapy (IMRT) plans with DP for prostate cancer. Twenty-four consecutive patients with locally advanced prostate cancer who underwent an multiparametric-magnetic resonance imaging (MP-MRI) (T2w, diffusion weighted image, dynamic contrast enhancement, and MRS) scan before a diagnostic biopsy from September 2015 to April 2016 were invited to take part in this study. The tumor local control probability (TCP) values for 3D-CRT, IMRT, and DP techniques were 45, 56, and 77%, respectively. The DP technique had a 37.5 and 71% higher TCP than IMRT and 3D-CRT, and these differences were statistically significant (P=0.001). The mean normal tissue complication probability (NTCP) values of the organ at risks for 3D-CRT, IMRT, and DP showed that there were statistically significant differences among them in three plans (P=0.01). DP by contours using MP-MRI is technically feasible. This study evaluated biological modeling based on both MP-MRI defined subvolumes and pathologically defined subvolumes. The MPMRI- guided DP results in better TCP/NTCP than 3D-CRT and IMRT.
Keywords
Full Text:
PDFReferences
Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010;76: S10-9.
Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990-6.
Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Movsas B, Epstein BE, et al. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 1998;41: 501-10.
Zelefsky M, Leibel S, Gaudin P, Kutcher G, Fleshner N, Venkatramen E, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998;41:491-500.
Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Miller DW, Adams JA, et al. Comparison of conventional-dose vs highdose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 2005;294:1233-9.
Dearnaley D, Sydes M, Graham J, Aird E, Bottomley D, Cowan R, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;8:475-87.
Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the MD Anderson randomized dose escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67-74.
Al-Mamgani A, van Putten WL, van der Wielen GJ, Levendag PC, Incrocci L. Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: Long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). Int J Radiat Oncol Biol Phys 2011;79:1004-12.
Beckendorf V, Guerif S, Le Prisé E, Cosset J-M., Bougnoux A, Chauvet B, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5 Year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011;80:1056-63.
Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McManus PL, et al. Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 1995;32:3-12.
Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: A meta analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009;74:1405-18.
Ghai S, Haider MA. Multiparametric-MRI in diagnosis of prostate cancer. Indian J Urol 2015;31:194-201.
Jomehzadeh A, Shokrani P, Mohammadi M, Amouheidari A. A quality assurance program for an amorphous silicon electronic portal imaging device using in-house developed phantoms: A method development for dosimetry purposes. Int J Radiat Res 2014;12:257-64.
Skyt PS, Petersen JB, Yates ES, Poulsen PR, Ravkilde TL, Balling P, et al. Dosimetric verification of complex radiotherapy with a 3D optically based dosimetry system: Dose painting and target tracking. Acta Oncol 2013;52:1445-50.
Chang JH, Joon DL, Lee ST, Gong SJ, Anderson NJ, Scott AM, et al. Intensity modulated radiation therapy dose painting for localized prostate cancer using 11 C-choline positron emission tomography scans. Int J Radiat Oncol Biol Phys 2012;83:e691-6.
Nahum AE, Uzan J. (Radio) biological optimization of externalbeam radiotherapy. Comput Math Methods Med 2012;2012.
Uzan J, Nahum A, Syndikus I. Prostate dose-painting radiotherapy and radiobiological guided optimisation enhances the therapeutic ratio. Clin Oncol 2016;28:165-70.
Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-32.
RTO Group. A Phase III Randomized Study of High-Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer. RTOG Report 0126;2004.
Li XA, Alber M, Deasy JO, Jackson A, Jee K-W, Marks LB, et al. The use and QA of biologically related models for treatment planning: Short report of the TG-166 of the therapy physics committee of the AAPM. Med Phys 2012;39:1386-409.
van Lin EN, Fütterer JJ, Heijmink SW, van der Vight LP, Hoffmann AL, van Kollenburg P, et al. IMRT boost dose planning on dominant intraprostatic lesions: Gold marker-based threedimensional fusion of CT with dynamic contrast-enhanced and 1Hspectroscopic MRI. Int J Radiat Oncol Biol Phys 2006;65:291-303.
Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A. Timing of biochemical failure and distant metastatic disease for low intermediate, and high-risk prostate cancer after radiotherapy. Cancer 2007;110:68-80.
Thorwarth D, Notohamiprodjo M, Zips D, Muller AC. Personalized precision radiotherapy by integration of multi-parametric functional and biological imaging in prostate cancer: A feasibility study. Z Med Phys 2017;27:21-30. pii: S0939-3889 (16)00022-2.
Toner L, Weerakoon M, Bolton DM, Ryan A, Katelaris N, Lawrentschuk N. Magnetic resonance imaging for prostate cancer: Comparative studies including radical prostatectomy specimens and template transperineal biopsy. Prostate Int 2015;3:107-14.
McPartlin A, Li XA, Kershaw LE, Heide U, Kerkmeijer L, Lawton C, et al. MRI-guided prostate adaptive radiotherapy -A systematic review. Radiother Oncol 2016;119;371-80.
Refbacks
- There are currently no refbacks.
https://e-rasaneh.ir/Certificate/22728
ISSN : 2228-7477